These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 12117077)

  • 1. Current issues on resistance, treatment guidelines, and the appropriate use of fluoroquinolones for respiratory tract infections.
    Bishai W
    Clin Ther; 2002 Jun; 24(6):838-50; discussion 837. PubMed ID: 12117077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
    Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):77-84. PubMed ID: 12376036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections?
    Momméja-Marin H; Carbon C
    Drugs; 1999 Jun; 57(6):851-3. PubMed ID: 10400400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.
    Balfour JA; Lamb HM
    Drugs; 2000 Jan; 59(1):115-39. PubMed ID: 10718103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
    Martin SJ; Jung R; Garvin CG
    Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A critical review of the fluoroquinolones: focus on respiratory infections.
    Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
    Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
    Pfaller MA; Ehrhardt AF; Jones RN
    Am J Med; 2001 Dec; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter evaluation of the efficacy and safety of gatifloxacin in Mexican adult outpatients with respiratory tract infections.
    Casillas JL; Rico G; Rodríguez-Parga D; Mascareño A; Rangel-Frausto S
    Adv Ther; 2000; 17(6):263-71. PubMed ID: 11317829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
    Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.
    Ambrose PG; Grasela DM; Grasela TH; Passarell J; Mayer HB; Pierce PF
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2793-7. PubMed ID: 11557471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program.
    Gordon KA; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2003 Aug; 46(4):285-9. PubMed ID: 12944021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections.
    Blasi F; Tarsia P; Cosentini R; Cazzola M; Allegra L
    Expert Opin Investig Drugs; 2003 Jul; 12(7):1165-77. PubMed ID: 12831351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Respiratory pathogens: assessing resistance patterns in Europe and the potential role of grepafloxacin as treatment of patients with infections caused by these organisms.
    Felmingham D
    J Antimicrob Chemother; 2000 Mar; 45():1-8. PubMed ID: 10719006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of fluoroquinolones in respiratory tract infections: community acquired pneumonia.
    García-Rodríguez JA; Muñoz Bellido JL
    Int J Antimicrob Agents; 2000 Nov; 16(3):281-5. PubMed ID: 11091048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin.
    Simoens S; Decramer M
    Expert Opin Pharmacother; 2008 Jul; 9(10):1735-44. PubMed ID: 18570606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
    Cantón R; Lode H; Graninger W; Milkovich G
    Int J Antimicrob Agents; 2006 Sep; 28 Suppl 2():S115-27. PubMed ID: 16904873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.
    Nightingale CH
    Pharmacotherapy; 2000 Mar; 20(3):245-56. PubMed ID: 10730681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging resistance problems among respiratory tract pathogens.
    Lister PD
    Am J Manag Care; 2000 May; 6(8 Suppl):S409-18. PubMed ID: 10977480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Community-acquired lower respiratory tract infections: etiology and treatment.
    Guthrie R
    Chest; 2001 Dec; 120(6):2021-34. PubMed ID: 11742937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemifloxacin: survival of the fittest.
    Mandell L
    J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():33-7. PubMed ID: 10997597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.